Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comparison of attitudes and knowledge of pre-exposure prophylaxis (PrEP) between hospital and Key Population Led Health Service providers: Lessons for Thailand's Universal Health Coverage implementation.
Rayanakorn A, Chautrakarn S, Intawong K, Chariyalertsak C, Khemngern P, Olson D, Chariyalertsak S. Rayanakorn A, et al. Among authors: intawong k. PLoS One. 2022 May 12;17(5):e0268407. doi: 10.1371/journal.pone.0268407. eCollection 2022. PLoS One. 2022. PMID: 35551288 Free PMC article.
Reduction in severity and mortality in COVID-19 patients owing to heterologous third and fourth-dose vaccines during the periods of delta and omicron predominance in Thailand.
Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W, Ayood P, Thongprachum A, Chotirosniramit N, Noppakun K, Khwanngern K, Teacharak W, Piamanant P, Khammawan P. Intawong K, et al. Int J Infect Dis. 2023 Jan;126:31-38. doi: 10.1016/j.ijid.2022.11.006. Epub 2022 Nov 11. Int J Infect Dis. 2023. PMID: 36372363 Free PMC article.
Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand: a test-negative, case-control study.
Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W, Thongprachum A, Chotirosniramit N, Teacharak W, Pimpinan Khammawan, Waneesorn J, Iamsirithaworn S. Intawong K, et al. Lancet Reg Health Southeast Asia. 2023 Mar;10:100121. doi: 10.1016/j.lansea.2022.100121. Epub 2022 Nov 29. Lancet Reg Health Southeast Asia. 2023. PMID: 36465090 Free PMC article.
Waning vaccine response to severe COVID-19 outcomes during omicron predominance in Thailand.
Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W, Thongprachum A, Chotirosniramit N, Noppakun K, Khwanngern K, Teacharak W, Piamanant P, Chantaklang P, Khammawan P. Intawong K, et al. PLoS One. 2023 May 11;18(5):e0284130. doi: 10.1371/journal.pone.0284130. eCollection 2023. PLoS One. 2023. PMID: 37167215 Free PMC article.
Heterologous booster vaccines reduce severity and mortality in COVID-19 during BA.2 and BA.4/BA.5 omicron predominance in Thailand.
Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W, Thongprachum A, Chotirosniramit N, Noppakun K, Khwanngern K, Teacharak W, Piamanant P, Khammawan P, Iamsirithaworng S. Intawong K, et al. J Microbiol Immunol Infect. 2023 Dec;56(6):1178-1186. doi: 10.1016/j.jmii.2023.10.001. Epub 2023 Oct 18. J Microbiol Immunol Infect. 2023. PMID: 37880062 Free article.
Experiences and challenges of pre-exposure prophylaxis initiation and retention among high-risk populations: qualitative insights among service providers in Thailand.
Rayanakorn A, Chautrakarn S, Intawong K, Chariyalertsak C, Khemngern P, Olson D, Chariyalertsak S. Rayanakorn A, et al. Among authors: intawong k. Front Public Health. 2024 May 15;12:1366754. doi: 10.3389/fpubh.2024.1366754. eCollection 2024. Front Public Health. 2024. PMID: 38813431 Free PMC article.
11 results